PTSD Clinical Trial
Official title:
Peer-led Trauma Therapy for Re-entry
The purpose of the research is to learn more about how to treat PTSD for people directly impacted by incarceration (i.e., have spent time in prison or jail). This research will help identify if a PTSD treatment group that is used in community settings, and led by individuals with lived experience, is helpful in reducing PTSD symptoms among people who have been directly impacted by incarceration. Participants will complete an interview to determine whether they are experiencing PTSD, and if so, will participate in a 6-week therapy group treatment.
Status | Recruiting |
Enrollment | 72 |
Est. completion date | September 2025 |
Est. primary completion date | September 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 18 years of age or older - completed a prison or jail sentence - no current psychosis symptoms - no active self-harm or active suicidal intent - able and willing to participate in group therapy - meet criteria for PTSD treatment need Exclusion Criteria: - current and active psychosis - current and active self-harm and suicidality - no PTSD diagnosis - current substance use dependence (not including those used as prescribed for medical reasons) on cocaine, amphetamines, inhalants, sedatives or sleeping pills, hallucinogens, or opioids |
Country | Name | City | State |
---|---|---|---|
United States | University of Wisconsin | Madison | Wisconsin |
Lead Sponsor | Collaborator |
---|---|
University of Wisconsin, Madison |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility: Participation | Will be measured as the percentage of invited, eligible individuals who elect to participate. | Study duration (up to 2 years) | |
Primary | Feasibility: Rate of retention | Will be measured by percentage of participants who complete at least 9 of the 12 study sessions | Study duration (up to 2 years) | |
Primary | Feasibility: Compliance through participation | Will be measured by percentage of participants performing intervention activities during session, such as contributing to the discussion. | Study duration (up to 2 years) | |
Primary | Feasibility: Compliance through homework | Will be measured by percentage of participants completing homework assignments each week. | Study duration (up to 2 years) | |
Primary | Feasibility: Compliance through completing assessments | Will be measured by percentage of participants completing the pre-, mid-, and post-intervention assessment batteries. | Study duration (up to 2 years) | |
Primary | Ratings from 0-5 by clinical supervisors on therapist adherence to five session elements | Higher ratings indicate better adherence to session elements. Assesses for therapist adherence to CPT guidelines as secondary measure of intervention efficacy. | Study duration (up to 2 years) | |
Primary | Ratings 1-7 by clinical supervisors on quality of session elements delivered by therapist | Higher ratings indicate higher-quality session element (scores 1-7; 1=not satisfactory, 4= satisfactory, 7=excellent) by the clinical supervisor. Assesses for therapist compliance as secondary measure of intervention efficacy. | Study duration (up to 2 years) | |
Primary | Change in suicide and self-harm ideation | Beck Depression Inventory-II (BDI-II), item 9. Participants will answer the item on a scale of 0-3, where a score of 2 or 3 indicates higher ideation. | Baseline to end of follow-up (up to 4.5 months) | |
Primary | Participant satisfaction | Using the 8 item Client Satisfaction Questionnaire (CSQ-8), participants will rate their satisfaction with their experience. Scale ranges from 1-4, with total potential scores of 8 to 32 with higher scores indicating greater satisfaction. | One week post-treatment (up to 7 weeks) | |
Primary | Change in PTSD symptom severity | Using the PTSD Checklist for DSM-5 (PCL-5), which is a 20-item self-report measure, symptoms of PTSD will be assessed. Participants will answer items on a scale of 0-4, where 0=Not at all and 4=Extremely. Higher scores indicate higher symptom severity. | Baseline to end of follow-up (up to 4.5 months) | |
Secondary | Change in depression symptom severity | Beck Depression Inventory-II (BDI-II), which is a 21-item self-report measure to assess depression severity. Participants will answer items on a scale of 0-3, where lower scores indicate lower severity. | Baseline to end of follow-up (up to 4.5 months) | |
Secondary | Change in trauma related thoughts and beliefs | Posttraumatic Cognitions Inventory (PTCI) is a 33-item measure of negative cognition about the world, negative self-related thoughts, and self-blame. Participants rate each item on a scale of 1-7, 1=totally disagree, 4=neutral, 7=totally agree. Higher scores indicate greater levels of trauma. | Baseline to end of follow-up (up to 4.5 months) | |
Secondary | Change in aspects of hopelessness | Beck Hopelessness Scale is a 20-item questionnaire, which participants answer true or false. | Baseline to end of follow-up (up to 4.5 months) | |
Secondary | Change in substance use | Tobacco, Alcohol, Prescription Medication, and other Substance Use Tool (TAPS) screens for tobacco use, alcohol use, prescription medication misuse, and illicit substance use in the past year, as well as the past 3 months. | Baseline to end of follow-up (up to 4.5 months) | |
Secondary | Change in anxiety symptom severity | Beck Anxiety Inventory (BAI), which is a 21-item self-report measure to assess anxiety severity. Participants will rate how much items bothered them as: Not at all; Mildly but it didn't bother me much; Moderately - it wasn't pleasant at times; or, Severely - it bothered me a lot. More symptoms that caused moderate or severe bother indicate higher severity of anxiety. | Baseline to end of follow-up (up to 4.5 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03962504 -
Written Exposure Therapy Versus Prolonged Exposure: a Non-inferiority Trial
|
N/A | |
Completed |
NCT01995123 -
Behavioral Activation for Smoking Cessation in PTSD
|
N/A | |
Not yet recruiting |
NCT06278922 -
Evaluating Signs of Safety: A Deaf-Accessible Therapy Toolkit for AUD and Trauma
|
N/A | |
Completed |
NCT04597450 -
Lu AG06466 in Participants With Post Traumatic Stress Disorder (PTSD)
|
Phase 1 | |
Completed |
NCT03593772 -
Mission Reconnect- Delivering a Mobile and Web Based Self Directed Complementary And Integrative Health Program to Veterans and Their Partners to Manage Pain and PTSD
|
N/A | |
Completed |
NCT03429166 -
Connecting Women to Care: Home-based Psychotherapy for Women With MST Living in Rural Areas
|
N/A | |
Recruiting |
NCT04317820 -
Deep Brain Reorienting in Post-traumatic Stress Disorder
|
N/A | |
Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
Completed |
NCT03504722 -
Evaluating the Feasibility of RESCUE: An Adjunctive HAI-Based Intervention for Veterans With PTSD
|
N/A | |
Completed |
NCT04305353 -
Intensive Care Unit (ICU) Diary Project
|
N/A | |
Completed |
NCT03113890 -
McLean and Genomind Prospective Study
|
N/A | |
Withdrawn |
NCT05173831 -
Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans
|
Phase 2 | |
Not yet recruiting |
NCT04056767 -
Changes in Digital Phenotype During PE Therapy
|
||
Withdrawn |
NCT03924297 -
Chilipad for Sleep and Symptoms of PTSD
|
N/A | |
Withdrawn |
NCT03216356 -
Effect of D-cycloserine on a Short Imagery Rescripting Intervention for Subclinical PTSD
|
Phase 2/Phase 3 | |
Completed |
NCT03343028 -
Biomarker Establishment for Superior Treatment of PTSD
|
||
Completed |
NCT03158558 -
Intensive Weekend Retreat Multi-Couple Group Therapy for PTSD
|
N/A | |
Completed |
NCT02370173 -
A Non-Pharmacological Method for Enhancing Sleep in PTSD
|
N/A | |
Completed |
NCT01911585 -
Efficacy of 60-minute Versus 90-minute Sessions in Treating PTSD Using Prolonged Exposure
|
N/A | |
Completed |
NCT01955538 -
The Effect of BAT Versus Mixed Physical Activity as add-on Treatment for Traumatised Refugees.
|
Phase 3 |